Gale R P, Butturini A
Department of Medicine, UCLA School of Medicine 90024-1678.
Exp Hematol. 1990 Sep;18(8):958-64.
Molecularly cloned hematopoietic growth factors are likely to be useful in treating persons with bone marrow failure resulting from radiation exposure. Some effects, such as increased granulocytes or platelets, are of clear therapeutic benefit. Other effects, such as a direct action on survival of hematopoietic stem cells and improved granulocyte function, may also increase survival. Many important areas remain to be studied, including which molecularly cloned hematopoietic growth factor(s) to use, optimal dose and timing, and others. Some of these issues can be studied in clinical trials; others require in vitro or animal models. Despite the limited data currently available, it is clear that the availability of molecularly cloned hematopoietic growth factors heralds a new era in treating radiation and nuclear accidents.
分子克隆的造血生长因子可能有助于治疗因辐射暴露导致骨髓衰竭的患者。一些效应，如粒细胞或血小板增加，具有明确的治疗益处。其他效应，如对造血干细胞存活的直接作用和改善粒细胞功能，也可能提高生存率。许多重要领域仍有待研究，包括使用哪种分子克隆的造血生长因子、最佳剂量和时机等。其中一些问题可以在临床试验中研究；其他问题则需要体外或动物模型。尽管目前可用的数据有限，但很明显，分子克隆的造血生长因子的出现预示着治疗辐射和核事故的新时代。
